[New treatment strategy for stage III non-small-cell lung cancer].
Yoh
Kiyotaka
K
Thoracic Oncology Division, National Cancer Center Hospital East.
Kubota
Kaoru
K
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D018288:Carcinoma, Small Cell / Q000473:pathology / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D000077143:Docetaxel; D000077156:Gefitinib; D006801:Humans; D000077146:Irinotecan; D008175:Lung Neoplasms / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage / Q000031:analogs & derivatives*; D011799:Quinazolines / Q000008:administration & dosage; D011878:Radiotherapy / Q000379:methods; D043823:Taxoids; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage
D011799:Quinazolines; D043823:Taxoids; D000077143:Docetaxel; D014747:Vinblastine; D000077146:Irinotecan; D017239:Paclitaxel; D002945:Cisplatin; D000077156:Gefitinib; D002166:Camptothecin